Replies to post #146197 on NanoViricides Inc. (NNVC)

[sunspotter]

"The decision to close the clinical trial with healthy subjects study completed was taken because diligent efforts to identify suitable COVID-19 participants for the clinical trials were met with a notable absence of positive cases at the designated clinical trial sites, despite addition of a second site during January/February 2024.

Both the single ascending dose part of this clinical trial (called Phase 1a), and the subsequent multiple ascending dose part (called Phase 1b) have been completed with healthy subjects. There were no reported adverse effects."

(My emphases.)

Somewhat implausible as in every real study ever conducted even placebo has reported adverse events.

And if that were true (which I doubt) failure to determine a maximum tolerated dose (MTD) would be a profound setback for any drug development program.

In any case they claim to have shown safety (but not an MTD) but have zero efficacy data.

Not exactly a strong platform to build upon. Or to speculate upon, for that matter.